Cholangitis

Aramchol, a small molecule in the Galmed Pharmaceuticals pipeline, prevented and reversed inflammation and scarring (fibrosis) of the bile ducts in mouse models of…

The American Liver Foundation (ALF) is launching a first-of-its kind national database, called the ALF Living Donor Network, to connect people willing to…

October is National Liver Awareness Month and Liver Cancer Awareness Month, and advocacy organizations across the U.S., including the American Liver Foundation (ALF), are…

Adults with autoimmune liver disease experience lower quality of life, especially those with primary biliary cholangitis (PBC), who report more fatigue, sleepiness, and pain…

Enrollment is complete in the Phase 2b VISTAS clinical trial, which is testing the experimental oral treatment volixibat in people with itching due to…

Intercept Pharmaceuticals has voluntarily withdrawn Ocaliva (obeticholic acid), an oral therapy used to treat certain adults with primary biliary cholangitis (PBC), from…

Members of the primary biliary cholangitis (PBC) community have come together in September as part of PBC Awareness Month to build support and share…

One year of treatment with saroglitazar, Zydus Therapeutics’ experimental oral candidate, outperformed a placebo at normalizing markers of liver injury in people with…

A blood marker of inflammation called lymphocyte-to-monocyte ratio (LMR) is an independent predictor of liver recompensation — when liver function improves with treatment despite permanent…

Chemomab Therapeutics has aligned with U.S. regulators on several aspects of the late-stage development of nebokitug, its candidate therapy for primary sclerosing cholangitis (PSC),…